{"title":"新生儿先天性巨细胞病毒筛查：美国现状","authors":"S. Nafday","doi":"10.46439/pediatrics.2.019","DOIUrl":null,"url":null,"abstract":"Targeted hearing screening for congenital cytomegalovirus (cCMV) with CMV polymerase chain reaction testing completed before 3 weeks of age for infants who fail newborn hearing screening is a reasonable option to improve cCMV related non-genetic sensory-neural hearing loss (SNHL). Universal cCMV screening using dried blood spots that is used on almost newborn infants has the potential to benefit those children at risk for SNHL and will be a great public health option.","PeriodicalId":93307,"journal":{"name":"Journal of clinical pediatrics and neonatology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Congenital Cytomegalovirus screening in newborns: Current status in the United States\",\"authors\":\"S. Nafday\",\"doi\":\"10.46439/pediatrics.2.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeted hearing screening for congenital cytomegalovirus (cCMV) with CMV polymerase chain reaction testing completed before 3 weeks of age for infants who fail newborn hearing screening is a reasonable option to improve cCMV related non-genetic sensory-neural hearing loss (SNHL). Universal cCMV screening using dried blood spots that is used on almost newborn infants has the potential to benefit those children at risk for SNHL and will be a great public health option.\",\"PeriodicalId\":93307,\"journal\":{\"name\":\"Journal of clinical pediatrics and neonatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical pediatrics and neonatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46439/pediatrics.2.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical pediatrics and neonatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46439/pediatrics.2.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Congenital Cytomegalovirus screening in newborns: Current status in the United States
Targeted hearing screening for congenital cytomegalovirus (cCMV) with CMV polymerase chain reaction testing completed before 3 weeks of age for infants who fail newborn hearing screening is a reasonable option to improve cCMV related non-genetic sensory-neural hearing loss (SNHL). Universal cCMV screening using dried blood spots that is used on almost newborn infants has the potential to benefit those children at risk for SNHL and will be a great public health option.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
